Key result
Iohexol clearance detects an ~8-point GFR decline in heart failure missed by creatinine-based equations.
Why the study?
Does iohexol plasma clearance outperform creatinine-based renal function estimating equations in detecting short-term longitudinal renal function decline in patients with chronic heart failure?
Cohort (n=43)
No
Does iohexol plasma clearance outperform creatinine-based renal function estimating equations in detecting short-term longitudinal renal function decline in patients with chronic heart failure?
Standard creatinine-based eGFR equations fail to detect clinically relevant short-term declines in true glomerular filtration rate among stable chronic heart failure patients, particularly those taking mineralocorticoid receptor antagonists.
Answers are grounded in this paper and cite their sources.
Creatinine-based eGFR may miss short-term GFR decline in chronic HF; hypothesis-generating for measured GFR, requiring prospective validation before adoption.
AIM: To compare the performance of iohexol plasma clearance and creatinine-based renal function estimating equations in monitoring longitudinal renal function changes in chronic heart failure (CHF) patients, and to assess the effects of body composition on the equation performance. METHODS: Iohexol plasma clearance was measured in 43 CHF patients at baseline and after at least 6 months. Simultaneously, renal function was estimated with five creatinine-based equations (four- and six-variable Modification of Diet in Renal Disease, Cockcroft-Gault, Cockcroft-Gault adjusted for lean body mass, Chronic Kidney Disease Epidemiology Collaboration equation) and body composition was assessed using bioimpedance and dual-energy x-ray absorptiometry. RESULTS: Over a median follow-up of 7.5 months (range 6-17 months), iohexol clearance significantly declined (52.8 vs 44.4 mL/[min ×1.73 m2], P=0.001). This decline was significantly higher in patients receiving mineralocorticoid receptor antagonists at baseline (mean decline -22% of baseline value vs -3%, P=0.037). Mean serum creatinine concentration did not change significantly during follow-up and no creatinine-based renal function estimating equation was able to detect the significant longitudinal decline of renal function determined by iohexol clearance. After accounting for body composition, the accuracy of the equations improved, but not their ability to detect renal function decline. CONCLUSIONS: Renal function measured with iohexol plasma clearance showed relevant decline in CHF patients, particularly in those treated with mineralocorticoid receptor antagonists. None of the equations for renal function estimation was able to detect these changes. ClinicalTrials.gov registration number: NCT01829880.
No takes yet. Share an insight, caveat, or question.
Trobec et al. (2015) conducted a cohort in Chronic heart failure (n=43). Iohexol plasma clearance measurement vs. Creatinine-based renal function estimating equations (CG, CGLBM, MDRD4, MDRD6, CKD-EPI) was evaluated on Longitudinal change in measured glomerular filtration rate (mGFR) via iohexol plasma clearance from baseline to follow-up (p=0.001). Iohexol plasma clearance detected a significant decline in renal function over a median of 7.5 months in chronic heart failure patients that was missed by all five creatinine-based estimating equations.
Synapse has enriched 10 related papers. Consider them for comparative context: